Shifting How the World Innovates

From our founding, we made the decision that we’d be different.

In the way we’re structured, in the people we hire, in our trials and technology—and in the way we research and innovate transformative solutions on the frontiers of oncology and autoimmune disease.

Shifting toward disease-centric therapies, we seek to treat patients holistically, allowing us to target diseases and their consequences on the human body on multiple levels.

Strategic priorities for biologics discovery research in immuno-oncology

FOCUS ON DISEASE-CENTRIC APPROACH AND LEVERAGE BEAT® ANTIBODY ENGINEERING PLATFORM TO DELIVER FIRST-IN-CLASS CANDIDATES
MULTIPLE MYELOMA (MM)
  • Optimize molecular attributes of ISB 1342 (CD38 x CD3) T-cell engager
  • Deliver a competitive MM portfolio by advancing next wave of T-cell engagers and innate immune engagers (e.g., NK, macrophages)
HEMATOLOGICAL MALIGNANCIES
  • Accelerate delivery of  innovative concepts by leveraging tri-specific T-cell and innate immune engagers (e.g., NK, macrophages)
SOLID TUMORS
  • Leverage BEAT® 2.0 in solid tumors

Shifting our approach to treating cancer

The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1

Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform, our Phase 1 immuno-oncology asset, ISB 1342, binds powerful immune cells called CD3 (or T cells) to CD38-expressing tumors.2 This approach has potential to treat patients with multiple myeloma, including those non-responsive or resistant to standard care.

Shifting novel autoimmune disease treatments forward

At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.

With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX40.3 By blocking OX40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3

ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions. The treatment may change lives, and the way autoimmune diseases are treated—from now on.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

  1. Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52:39-52 (2018).
  2. Ichnos Sciences’ ongoing clinical trial of ISB 1342 in relapsed refractory Multiple Myeloma. Available here. NLM identifier: NCT03309111
  3. Guttman-Yassky, E. et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J. Allergy Clin. Immunol. 144:482-493.e7 (2019). Available here.

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.